Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Shaping the future of acromegaly care: Insights from the updated consensus guidelines
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
“As many patterns as there are patients”: Dr. Elena Valassi on acromegaly myopathy and the hidden reach of cortisol
In this engaging discussion, we touch on why muscles stay weak in acromegaly even after the disease is under control, and why hypercortisolism keeps turning up in more people than anyone used to expect. Dr. Valassi’s earlier work on acromegaly and muscles got a lot of attention from PWN readers.
Worth noting:
Recordati announces FDA approval of ISTURISA® new indication in the U.S. to treat endogenous hypercortisolemia in patients with Cushing’s syndrome,- Learn more here
Corcept Therapeutics announces FDA Relacolirant new drug application to treat Hypercortisolism . Read more
From Crinetics Pharmaceuticals – FDA accepts Crinetics new drug Paltusotine’s application for adults with acromegaly . Read more
Camurus announces final results for the once-monthly octreotide subcutaneous treatment option for acromegaly. Read more
New support site from Chiesi; Rethink acromegaly
Pfizer announces Together with Acromegaly patient support site and Together for Rare: Understanding your insurance options video.
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
Latest Videos
Episode 2: From biomarkers to best practice
Professor Maria Fleseriu and Professor Mark Gurnell focus on predictors of response to medical therapy, including the role of imaging characteristics, pathological and molecular markers, and biochemical parameters in guiding treatment decisions to support individualized
Same Tumor, Scarier Name: What the PitNET Reclassification Means for You
This is my conversation with Dr. Ken Ho, Professor at St. Vincent’s Hospital, Sydney and Garvan Institute of Medical Research, Sydney, Australia, on why a single word could change how pituitary patients are treated, and why leading endocrinologists are asking the WHO (World Health Organization) to reconsider.
More from Endo 2026 and the fast moving world of pituitary medicine
I sat down with Dr. Leena Shahla, medical director of the Duke Pituitary Center to talk about the latest developments from ENDO 2026. Many in of our readers will remember her from an earlier Pituitary World News Podcast conversation with our co-founder, Dr. Lewis Blevins, on the tricky business of distinguishing pseudo-Cushing’s from the real thing. This time, the focus was the fast-moving world of acromegaly therapy.
How new cortisol research is reshaping patient advocacy
In this illuminating conversation I talk with Leslie Edwin, president of the Cushing Support and Research Foundation about the shifting data around hypercortisolism and its connection to type 2 diabetes and hypertension. Leslie frames the
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D. Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
At ENDO 2026, Dr. Richard Auchus of the University of Michigan shares his perspectives on the connection between type 2 diabetes and hard-to-control hypertension and high cortisol in Corcept Therapeutics’ landmark studies. The interview covers two related studies investigating how often “common” diseases—difficult-to-control diabetes and hypertension are actually being driven by undiagnosed adrenal dysfunction, particularly mild, clinically significant cortisol excess from adrenal adenomas.
Our live talk sessions of the pituitary and adrenal podcasts continue with this extremely informational conversation on hypothalamic obesity. If you are interested in learning more about his devastating disorder, please listen to Dr. Blevins as he shares his insights and extensive expertise on its causes, new treatments, and latest developments.
Apple Podcasts
Spotify
Amazon Music
Google Podcasts
